A new patient preference study has been published in The Oncologist, providing insight into how myeloma patients rationalise treatments.
Myeloma patients in the UK are being invited to take part in a study that is testing a new questionnaire which aims to support patients and their clinicians in discussing, addressing and better recording quality of life issues that matter patients.
Myeloma UK has launched MUK nine, the first UK-wide trial using state-of-the-art genetic techniques to ‘stratify’ treatment for so-called high-risk myeloma patients.
Patients in Scotland will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the Scottish Medicines Consortium (SMC) approved it for use.
National blood cancer charity, the Basil Skyers Myeloma Foundation, has published a new report which looks at diversity in myeloma […]
September is Blood Cancer Awareness Month, and throughout the month we are raising awareness of myeloma, its signs and symptoms […]
This August, Myeloma UK attended the first Oxford Myeloma Workshop, a two day event for scientists and healthcare professionals including […]
Myeloma UK-funded researchers at The Institute of Cancer Research have published new research into how studying specific genetic abnormalities in myeloma cells to help create more targeted and effective treatments.